FR10C0025I2 - Protéines de fusion du récepteur de IL-1 utilisées comme antagonistes et méthodes d'utilisation et de fabrication - Google Patents

Protéines de fusion du récepteur de IL-1 utilisées comme antagonistes et méthodes d'utilisation et de fabrication

Info

Publication number
FR10C0025I2
FR10C0025I2 FR10C0025C FR10C0025C FR10C0025I2 FR 10C0025 I2 FR10C0025 I2 FR 10C0025I2 FR 10C0025 C FR10C0025 C FR 10C0025C FR 10C0025 C FR10C0025 C FR 10C0025C FR 10C0025 I2 FR10C0025 I2 FR 10C0025I2
Authority
FR
France
Prior art keywords
methods
antagonists
manufacture
fusion proteins
receptor fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR10C0025C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of FR10C0025I1 publication Critical patent/FR10C0025I1/fr
Application granted granted Critical
Publication of FR10C0025I2 publication Critical patent/FR10C0025I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR10C0025C 1998-09-25 2010-04-16 Protéines de fusion du récepteur de IL-1 utilisées comme antagonistes et méthodes d'utilisation et de fabrication Active FR10C0025I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10185898P 1998-09-25 1998-09-25
US09/313,942 US6472179B2 (en) 1998-09-25 1999-05-19 Receptor based antagonists and methods of making and using
EP99952942A EP1115876B1 (fr) 1998-09-25 1999-09-22 Antagonistes a base de recepteurs, modes d'elaboration et d'utilisation

Publications (2)

Publication Number Publication Date
FR10C0025I1 FR10C0025I1 (fr) 2010-05-21
FR10C0025I2 true FR10C0025I2 (fr) 2011-04-01

Family

ID=26798712

Family Applications (1)

Application Number Title Priority Date Filing Date
FR10C0025C Active FR10C0025I2 (fr) 1998-09-25 2010-04-16 Protéines de fusion du récepteur de IL-1 utilisées comme antagonistes et méthodes d'utilisation et de fabrication

Country Status (19)

Country Link
US (2) US6472179B2 (fr)
EP (3) EP1405915A1 (fr)
JP (1) JP3902728B2 (fr)
CN (1) CN100345970C (fr)
AT (2) ATE336583T1 (fr)
AU (1) AU758970C (fr)
BE (1) BE2010C021I2 (fr)
CA (1) CA2345109C (fr)
DE (3) DE69922269T2 (fr)
DK (1) DK1229047T3 (fr)
ES (2) ES2267300T3 (fr)
FR (1) FR10C0025I2 (fr)
HK (2) HK1035377A1 (fr)
IL (2) IL142103A0 (fr)
NO (2) NO329976B1 (fr)
NZ (1) NZ510720A (fr)
PL (1) PL201246B1 (fr)
PT (1) PT1229047E (fr)
WO (1) WO2000018932A2 (fr)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
NZ505880A (en) * 1998-01-23 2003-06-30 Immunex Corp IL-18 receptor polypeptides
US7083949B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US20040120891A1 (en) * 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
ES2614260T3 (es) 2000-05-26 2017-05-30 Immunex Corporation Uso de anticuerpos contra el receptor de interleuquina-4 y composiciones de los mismos
JP4660062B2 (ja) * 2000-06-16 2011-03-30 アステリオン・リミテッド 結合剤
JP5015404B2 (ja) 2000-08-08 2012-08-29 ザイモジェネティクス， インコーポレイテッド 可溶性ｚｃｙｔｏｒ１１サイトカイン受容体
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20050112616A1 (en) * 2001-12-10 2005-05-26 William Lee Functionalized materials and libraries thereof
US7795213B2 (en) * 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
US6846520B2 (en) * 2002-01-17 2005-01-25 Canon Kabushiki Kaisha Epoxy resin composition, surface treatment method, liquid-jet recording head and liquid-jet recording apparatus
WO2003092610A2 (fr) * 2002-05-01 2003-11-13 Regeneron Pharmaceuticals, Inc. Procedes d'utilisation des antagonistes des cytokines dans le traitement de l'infection par le vih et le sida
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
CN101124244B (zh) 2002-11-15 2012-10-10 根马布股份公司 抗cd25的人单克隆抗体
US6919012B1 (en) 2003-03-25 2005-07-19 Olimex Group, Inc. Method of making a composite article comprising a ceramic coating
WO2004085478A2 (fr) 2003-03-26 2004-10-07 Apogenix Gmbh Proteines hybrides fc ameliorees
WO2004100987A2 (fr) * 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Procede d'utilisation d'antagonistes de l'il1 pour le traitement d'hyperplasie neointimale
WO2004098596A1 (fr) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprenant roflumilast et il-1 trap
US20050118683A1 (en) * 2003-06-11 2005-06-02 Wood Clive R. Method for producing a polypeptide
HUE050171T2 (hu) * 2003-07-28 2020-11-30 Genentech Inc Protein-A kioldódásának csökkentése protein-A affinitáskromatográfia során
CA2536936A1 (fr) * 2003-09-05 2005-03-17 National Research Council Of Canada Proteine hybride bispiralee avec domaines de recepteurs cellulaires
KR101225463B1 (ko) 2003-11-07 2013-01-24 임뮤넥스 코포레이션 인터류킨-4 수용체에 결합하는 항체
AU2005219837A1 (en) 2004-02-27 2005-09-15 Regeneron Pharmaceuticals, Inc. IL-4/IL-13 sepecific polypetides and therapeutic uses thereof
CA2568352C (fr) 2004-06-04 2011-09-13 Regeneron Pharmaceuticals, Inc. Procedes d'utilisation d'antagonistes de l'il-1 dans le traitement de maladies auto-inflammatoires
ES2426005T3 (es) 2004-07-23 2013-10-18 Acceleron Pharma Inc. Polipéptidos del receptor ACTRII, procedimientos y composiciones
DK1778723T3 (da) * 2004-08-17 2012-12-03 Regeneron Pharma Il-1-antagonistformuleringer
PT1630232E (pt) * 2004-08-27 2008-10-02 Conaris Res Inst Ag Sequências de nucleótidos optimizadas que codificam sgp130
US7786261B2 (en) * 2004-09-02 2010-08-31 National Research Council Of Canada Coiled-coil fusion proteins comprising cell receptor domains
PL2229956T3 (pl) * 2004-09-13 2013-09-30 Genzyme Corp Konstrukty multimeryczne
MX2007004374A (es) * 2004-10-12 2008-01-29 Amprotein Corp Proteina quimerica.
BRPI0516975A (pt) 2004-10-22 2008-09-30 Zymogenetics Inc anticorpo ou seu fragmento de ligação a antìgeno, composição farmacêutica, imunoconjugado, hibridoma, anticorpo monoclonal, e, uso de um anticorpo ou seu fragmento de ligação a antìgeno
EP1848738A1 (fr) * 2005-01-25 2007-10-31 Apollo Life Sciences Limited Gm-csf, il-3, il-4, il-5 choisis en fonction de parametres et leurs chimeres dans des applications therapeutiques et diagnostiques
ES2548238T3 (es) 2005-03-25 2015-10-15 Regeneron Pharmaceuticals, Inc. Formulaciones antagonistas de VEGF
US7732167B2 (en) * 2005-06-17 2010-06-08 Regeneron Pharmaceuticals, Inc. Interferon-α/β binding fusion proteins and therapeutic uses thereof
US7608430B2 (en) * 2005-07-08 2009-10-27 Regeneron Pharmaceuticals, Inc. Interferon-γ antagonists and therapeutic uses thereof
EP2298815B1 (fr) 2005-07-25 2015-03-11 Emergent Product Development Seattle, LLC Reduction de lymphocytes B au moyen de molecules de liaison specifique de CD37 et specifique de CD20
US7666622B2 (en) * 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US7889347B2 (en) 2005-11-21 2011-02-15 Plexera Llc Surface plasmon resonance spectrometer with an actuator driven angle scanning mechanism
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
KR20180030264A (ko) * 2005-11-23 2018-03-21 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도
US7463358B2 (en) 2005-12-06 2008-12-09 Lumera Corporation Highly stable surface plasmon resonance plates, microarrays, and methods
CA2646965C (fr) 2006-03-24 2016-06-21 Jonathan H. Davis Domaines de proteine heterodimerique d'ingenierie
WO2007146968A2 (fr) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Protéines de liaison monocaténaires polyvalentes dotées d'une fonction d'effecteur
DK2944306T3 (da) 2006-06-16 2021-03-08 Regeneron Pharma Egnede VEGF-antagonistformuleringer til intravitreal administration
ATE480568T1 (de) * 2006-06-30 2010-09-15 Conaris Res Inst Ag Verbesserte sgp 130fc dimere
JP5693004B2 (ja) * 2006-07-28 2015-04-01 チルドレンズ メモリアル ホスピタル ヒト胚性幹細胞の微小環境を使用して腫瘍細胞の悪性度を抑制する方法
US8106004B2 (en) * 2006-07-28 2012-01-31 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
EP2124997B1 (fr) * 2006-10-20 2012-08-08 Regeneron Pharmaceuticals, Inc. Utilisation d'antagonistes il-1 pour traiter la goutte ou la pseudo-goutte
US7632490B2 (en) * 2006-10-20 2009-12-15 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
JP5272735B2 (ja) * 2007-01-30 2013-08-28 国立大学法人 新潟大学 生物学的製剤
RU2473362C2 (ru) 2007-02-01 2013-01-27 Акселерон Фарма Инк. АНТАГОНИСТЫ АКТИВИНА-ActRIIa-Fc И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
EA018221B1 (ru) 2007-02-09 2013-06-28 Акселерон Фарма Инк. АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
EP2578684B1 (fr) * 2007-03-19 2016-02-24 National Research Council Of Canada Antagonistes de ligands et leurs utilisations
WO2009010539A2 (fr) * 2007-07-19 2009-01-22 Ablynx. N.V. Recepteur de l'interleukine-6 (il-6) derive de macaca fascicularis
CN107412734A (zh) 2007-09-18 2017-12-01 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
JP2011502163A (ja) * 2007-10-31 2011-01-20 ザ スクリプス リサーチ インスティテュート 持続性ウイルス感染を治療するための併用療法
US8004669B1 (en) 2007-12-18 2011-08-23 Plexera Llc SPR apparatus with a high performance fluid delivery system
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
DK3494986T3 (da) 2008-08-14 2020-08-03 Acceleron Pharma Inc GDF fanger
EP2326670A4 (fr) * 2008-09-17 2014-04-16 Nat Res Council Canada Agents de liaison hétéro-multivalents pour des membres de la superfamille des tgf-
KR101778134B1 (ko) 2008-11-26 2017-09-13 암젠 인크 액티빈 ｉｉｂ 수용체 폴리펩타이드의 변이체 및 이의 용도
EP3845239A1 (fr) 2009-06-08 2021-07-07 Acceleron Pharma Inc. Utilisation de protéines anti-actriib pour l'augmentation d'adipocytes thermogènes
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
AU2010322011B2 (en) 2009-11-17 2016-03-31 Acceleron Pharma Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
US20150359850A1 (en) 2009-11-25 2015-12-17 Santa Maria Biotherapeutics, Inc. Administration of an anti-activin-a compound to a subject
CA2817008A1 (fr) 2010-11-08 2012-05-18 Acceleron Pharma Inc. Agents de liaison a actriia et leurs utilisations
EP2697260A1 (fr) 2011-04-15 2014-02-19 Merck Patent GmbH Inhibiteurs anti-il-1r1 destinés à une utilisation dans le cadre du cancer
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
EP2793925B1 (fr) 2011-12-19 2019-03-20 Amgen Inc. Variants polypeptidiques du récepteur de l'activine, seuls ou en combinaison avec une chimiothérapie, et leurs utilisations
NZ707477A (en) 2012-11-02 2019-09-27 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
AU2013357427B2 (en) * 2012-12-10 2017-08-31 Universiteit Gent Novel Interleukin-33 inhibitors
NZ710900A (en) 2013-02-15 2019-09-27 R Pharm International Llc Il-1β inhibitor composition and use thereof
EP3154566B1 (fr) 2014-06-13 2022-08-03 Acceleron Pharma Inc. Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
CN107076750B (zh) 2014-07-18 2020-06-23 赛诺菲 用于预测疑似患有癌症的患者使用阿柏西普的治疗结果的方法
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
DK3226888T3 (da) 2014-12-01 2021-07-12 Ferring Bv Administration af en selektiv inhibitor af il-6-trans-signalering
MA41116A (fr) 2014-12-01 2017-10-10 Ferring Bv Compositions d'inhibiteur de trans-signalisation par l'il-6 sélectif
EP3227675B1 (fr) 2014-12-03 2023-03-15 Celgene Corporation Antagonistes de l'activine-actrii et leurs utilisations pour le traitement du syndrome myelodysplasique
GB201503453D0 (en) 2015-03-01 2015-04-15 Jain Arjun Endothelin-1"sponge"
SG10202002577XA (en) 2015-09-21 2020-04-29 Aptevo Res & Development Llc Cd3 binding polypeptides
WO2018064190A1 (fr) 2016-09-27 2018-04-05 Epicentrx, Inc. Protéines de fusion immunomodulatrices
EP3612555A4 (fr) * 2017-04-21 2020-12-30 Kindred Biosciences, Inc. Molécule récepteur d'il4/il13 à usage vétérinaire
CA3077223A1 (fr) 2017-09-27 2019-04-04 Epicentrx, Inc. Proteines de fusion immunomodulatrices
EA202091710A1 (ru) 2018-03-09 2021-02-16 Агенус Инк. Антитела против cd73 и способы их применения
US11897928B2 (en) 2018-07-18 2024-02-13 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
CN110950965B (zh) * 2018-09-26 2021-10-15 重庆精准生物技术有限公司 抗人cd123的嵌合抗原受体及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
AU651596B2 (en) * 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
DE59109032D1 (de) * 1990-06-28 1998-09-03 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre Herstellung und Verwendung
EP0533006A1 (fr) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimères constituées du récepteur de l'interleukine 5 et de polypeptides d'immunoglobulines
CA2121473C (fr) * 1991-10-15 2001-05-01 Michael Mullarkey Methodes et compositions pour le traitement de reactions allergiques
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
DE69321720T2 (de) * 1992-03-09 1999-05-06 Ludwig Inst Cancer Res Für den interleukin-9-rezeptor kodierende nukleinsäuresequenzen bzw. dafür komplementäre nuleinsäuresequenzen
US8211422B2 (en) * 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
WO1993019163A1 (fr) * 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Genes de recepteurs chimeres et cellules transformees au moyen desdits genes
NZ251820A (en) * 1992-03-30 1996-07-26 Immunex Corp Fusion proteins with tnf-r (tumour necrosis factor-receptor) peptide linked to another tnf-r or an il-1r (interleukin-1-receptor) peptide
JP3255699B2 (ja) 1992-04-23 2002-02-12 味の素株式会社 ヒトＩＬ−２レセプターγ鎖分子
US5747292A (en) * 1993-04-06 1998-05-05 Fred Hutchinson Cancer Research Center Chimeric cytokine receptors in lymphocytes
EP0716703A1 (fr) * 1993-09-03 1996-06-19 PRENDERGAST, Kenneth, Francis Compositions proteiques de fusion contenant la proteine de liaison a la glycophorine (gbp 130)
AU701623B2 (en) * 1993-10-14 1999-02-04 President And Fellows Of Harvard College Method of inducing and maintaining neuronal cells
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
IL114825A0 (en) * 1994-08-04 1995-12-08 Regeneron Pharma Rtk/cytokine receptor chimeras
AU3830895A (en) 1994-10-07 1996-05-02 Amgen Boulder Inc. Dimeric il-4 inhibitors
US6077947A (en) * 1995-02-02 2000-06-20 Cell Genesys, Inc. DNA encoding an intracellular chimeric receptor comprising Janus kinase
US5837816A (en) * 1995-05-10 1998-11-17 Chiron Corporation Interleukin-2 receptor subunit ectodomain fusion protein comprising a leucine zipper domain
GB9526131D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US5776731A (en) * 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
WO1998002558A2 (fr) * 1996-07-17 1998-01-22 University Of Medicine And Dentistry Of New Jersey Recepteurs chimeres pour transduction de signaux jak-stat
AU7011696A (en) * 1996-08-26 1998-03-19 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
GB9625899D0 (en) 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
NZ505880A (en) * 1998-01-23 2003-06-30 Immunex Corp IL-18 receptor polypeptides

Also Published As

Publication number Publication date
ATE336583T1 (de) 2006-09-15
NO20011513L (no) 2001-05-25
NZ510720A (en) 2003-11-28
HK1045847B (zh) 2005-03-24
AU758970C (en) 2007-05-03
FR10C0025I1 (fr) 2010-05-21
US20020164690A1 (en) 2002-11-07
ES2267300T3 (es) 2007-03-01
CA2345109A1 (fr) 2000-04-06
DK1229047T3 (da) 2005-02-21
IL142103A (en) 2007-07-04
JP2002525119A (ja) 2002-08-13
WO2000018932A3 (fr) 2000-11-02
CA2345109C (fr) 2012-12-18
DE122010000023I1 (de) 2012-04-26
DE69932832T2 (de) 2007-02-08
CN100345970C (zh) 2007-10-31
US20020012962A1 (en) 2002-01-31
NO2011003I1 (no) 2011-05-02
EP1405915A1 (fr) 2004-04-07
EP1229047A3 (fr) 2002-10-02
EP1115876A2 (fr) 2001-07-18
PL201246B1 (pl) 2009-03-31
BE2010C021I2 (fr) 2018-12-04
HK1035377A1 (en) 2001-11-23
DE122010000023I2 (de) 2012-04-26
DE69932832D1 (de) 2006-09-28
ES2233733T3 (es) 2005-06-16
AU758970B2 (en) 2003-04-03
DE69922269D1 (de) 2004-12-30
NO20011513D0 (no) 2001-03-23
ATE283365T1 (de) 2004-12-15
EP1229047B1 (fr) 2004-11-24
EP1115876B1 (fr) 2006-08-16
PL348529A1 (en) 2002-06-03
WO2000018932A2 (fr) 2000-04-06
WO2000018932A9 (fr) 2000-08-31
CN1357049A (zh) 2002-07-03
NO329976B1 (no) 2011-01-31
HK1045847A1 (en) 2002-12-13
US6472179B2 (en) 2002-10-29
JP3902728B2 (ja) 2007-04-11
DE69922269T2 (de) 2005-12-01
EP1229047A2 (fr) 2002-08-07
IL142103A0 (en) 2002-03-10
AU6499499A (en) 2000-04-17
PT1229047E (pt) 2005-03-31
NO2011003I2 (fr) 2011-04-11

Similar Documents

Publication Publication Date Title
FR10C0025I2 (fr) Protéines de fusion du récepteur de IL-1 utilisées comme antagonistes et méthodes d'utilisation et de fabrication
IL168050A (en) Il-1 receptor based antagonists and methods of making them and reagents for use therein
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
EA200600126A1 (ru) Антитела против tnf, композиции, способы и применения
TR200001861T2 (tr) Yeni G protein birleştirilmiş alıcı
CY1112101T1 (el) Νευροτροφικοι παραγοντες
WO2004003147A3 (fr) Polypeptides cngh0004, anticorps, compositions, procedes et utilisations
ATE519847T1 (de) Il-17-homologe polypeptide und ihre therapeutische verwendung
DK1321477T3 (da) Fremgangsmåde til frembringelsen af genetisk modificerede vertebrate precursor-lymfocytter og anvendelse deraf til fremstillingen af heterologe bindende proteiner
SE9801455D0 (sv) New receptor
WO2004043403A3 (fr) Polypeptides synthetiques a domaine unique imitant l'apolipoproteine e et methodes d'utilisation
ATE443761T1 (de) Rtd receptor
SE9602822D0 (sv) New receptor
EA200400392A1 (ru) Связывающий каспазу-8 белок, его получение и применение
DE60130804D1 (de) Antagonistischer antikörper gegen pro842
SE9804274D0 (sv) Novel receptor
SE9604439D0 (sv) New receptor
DE60236143D1 (de) Gewebe transglutaminase
WO2000006733A3 (fr) Proteines des recepteurs des lymphocytes t, molecules d'acide nucleique et utilisation de ces dernieres
SE0002364D0 (sv) Growth Factors